pld2

VU0155069 strongly inhibits the invasive migration of several cancer cell lines in transwell assays. VU0155069 is a selective phospholipase D1 inhibitor (IC50: 46 nM in vitro).

FIPI (5-Fluoro-2-indolyl deschlorohalopemide) is a derivative of halopemide which potently inhibits both PLD1 (IC50 = 25 nM) and PLD2 (IC50 = 20 nM); prevents PLD regulation of F-actin cytoskeleton reorganization, cell spreading, and chemotaxis.

CAY10594 is a potent phospholipase D2(PLD2) inhibitor. CAY10594 ameliorates acetaminophen-induced acute liver injury by regulating the phosphorylated-GSK-3β/JNK axis.

Halopemide is a potent inhibitor of PLD (IC50 = 220 and 310 nM for human PLD1 and PLD2). Halopemid is an antagonist of dopamine receptors. Halopemid can be used in psychotropic research.

VU0359595 (ML-270) is a potent and selective pharmacological phospholipase D1 (PLD1) inhibitor with an IC50 of 3.7 nM. VU0359595 is >1700-fold selective for PLD1 over PLD2 (IC50 of 6.4 μM). VU0359595 can be used for the research of cancer, diabetes, neurodegenerative and inflammatory diseases.

ML299 (VU0463568) is a dual PLD1 2 inhibitor (PLD1 and PLD2, IC50 of 6 nM, 20 nM, respectively).

VU0285655-1(BML-280) is a potent and selective phospholipase D2 (PLD2) inhibitor that inhibits the proliferation of PLD2-deficient cells.VU0285655-1 has an inhibitory effect on high glucose-induced caspase-3 cleavage and reduction of cell viability.VU0285655-1 is used in the study of diabetic retinopathy.

ML 298 hydrochloride is a phospholipase D2 (PLD2) inhibitor.

VU 0364739 hydrochloride (VU 0364739 HCl) is a selective and potent inhibitor of phospholipase D2 (PLD2) with IC50s of 20 and 1500 nM for PLD2 and PLD1, respectively.VU 0364739 hydrochloride exhibits potential anticancer activity and induces apoptosis. VU 0364739 hydrochloride has potential anticancer activity, induces apoptosis, and can be used in the study of cancer and metabolic-related diseases.

ML395 is a potent, selective PLD2 allosteric inhibitor with potent antiviral activity (IC50 =360 nM).

VU0155056 is a dual PLD1 2 inhibitor with IC50 = 81 nM for PLD1 and IC50 = 240 nM for PLD2 in in vitro assays, and IC50 < 1 µM in cellular assays, which inhibits breast cancer cell invasion.

Dioleoylphosphatidylglycerol (DOPG), a naturally occurring phospholipid, is synthesized through the action of aquaporin 3 (AQP3) and phospholipase D2 (PLD2). It functions to suppress the production of inflammatory mediators by macrophages triggered by the activation of toll-like receptor 2 (TLR2) by heat shock protein B4 (HSPB4) [1].

VU0364739, a selective phospholipase D2 (PLD2) inhibitor with an IC50 of 22 nM, effectively reduces cancer cell proliferation [1].

A4333, a biotinylated derivative of A3373, selectively inhibits Phospholipase D1 (PLD1) while sparing PLD2. It is noted for its significant role in antitumor activity [1].

A3373 is a novel inhibitor targeting both Phospholipase D1 (PLD1) and Phospholipase D2 (PLD2), demonstrating half maximal inhibitory concentrations (IC50) of 325 nM for PLD1 and 15.15μM for PLD2. This compound effectively suppresses lipopolysaccharide (LPS)-induced immune responses and is implicated in key processes of autoimmune arthritis, bone demineralization, and osteoclastogenesis [1] [2].

VU0155069 hydrochloride (CAY10593 hydrochloride) is a potent and selective inhibitor of phospholipase D (PLD), exhibiting IC50 values of 46 nM for PLD1 and 933 nM for PLD2. It effectively inhibits the migration of both human and mouse breast cancer cell lines [1] [2].

ML-298 (CID53393915) is a potent, specific inhibitor of Phospholipase D2 (PLD2, IC50 of 355 nM).

Desketoraloxifene is a selective estrogen receptor modulator, inhibiting mammalian PLD (PLD1 and PLD2).